JP2006503913A5 - - Google Patents

Download PDF

Info

Publication number
JP2006503913A5
JP2006503913A5 JP2005501572A JP2005501572A JP2006503913A5 JP 2006503913 A5 JP2006503913 A5 JP 2006503913A5 JP 2005501572 A JP2005501572 A JP 2005501572A JP 2005501572 A JP2005501572 A JP 2005501572A JP 2006503913 A5 JP2006503913 A5 JP 2006503913A5
Authority
JP
Japan
Prior art keywords
composition
benzalkonium chloride
composition according
ophthalmic
eye drop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005501572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503913A (ja
Filing date
Publication date
Priority claimed from US10/429,677 external-priority patent/US7074827B2/en
Application filed filed Critical
Publication of JP2006503913A publication Critical patent/JP2006503913A/ja
Publication of JP2006503913A5 publication Critical patent/JP2006503913A5/ja
Pending legal-status Critical Current

Links

JP2005501572A 2002-10-24 2003-10-22 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 Pending JP2006503913A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42077602P 2002-10-24 2002-10-24
US42104402P 2002-10-25 2002-10-25
US10/429,677 US7074827B2 (en) 2002-10-24 2003-05-06 Method for treating ocular hypertension and glaucoma
PCT/JP2003/013452 WO2004037267A1 (en) 2002-10-24 2003-10-22 Method and composition containing latanoprost for treating ocular hypertension and glaucoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012125019A Division JP2012162570A (ja) 2002-10-24 2012-05-31 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物

Publications (2)

Publication Number Publication Date
JP2006503913A JP2006503913A (ja) 2006-02-02
JP2006503913A5 true JP2006503913A5 (enExample) 2006-12-07

Family

ID=32110845

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005501572A Pending JP2006503913A (ja) 2002-10-24 2003-10-22 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物
JP2012125019A Pending JP2012162570A (ja) 2002-10-24 2012-05-31 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012125019A Pending JP2012162570A (ja) 2002-10-24 2012-05-31 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物

Country Status (9)

Country Link
US (2) US7074827B2 (enExample)
EP (2) EP1553953B1 (enExample)
JP (2) JP2006503913A (enExample)
AT (1) ATE480240T1 (enExample)
AU (1) AU2003274734A1 (enExample)
CA (1) CA2502437C (enExample)
DE (1) DE60334134D1 (enExample)
DK (1) DK1553953T3 (enExample)
WO (1) WO2004037267A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039619A1 (en) * 2003-10-03 2005-05-06 Allergan, Inc. Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
DE102005035986B4 (de) * 2005-07-28 2009-10-15 Bausch & Lomb Incorporated Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat
JP5247453B2 (ja) * 2005-10-10 2013-07-24 ノバガリ ファルマ エスア プロスタグランジン含有眼科用カチオン性水中油型エマルジョン
US7666912B2 (en) * 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
PL2066300T5 (pl) * 2006-09-28 2020-03-31 Novartis Ag Samokonserwujące wodne kompozycje farmaceutyczne
FR2912207B1 (fr) * 2007-02-01 2012-10-26 Air Liquide Procede et appareil de production de monoxyde de carbone par distillation cryogenique
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
JP2008247828A (ja) * 2007-03-30 2008-10-16 Wakamoto Pharmaceut Co Ltd ラタノプロストを含有する水性医薬組成物。
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
JP2009040727A (ja) * 2007-08-09 2009-02-26 Towa Yakuhin Kk ラタノプロストを有効成分とする安定な点眼液剤
ES2511840T3 (es) * 2007-08-29 2014-10-23 Wakamoto Pharmaceutical Co., Ltd. Composición farmacéutica acuosa que contiene latanoprost
MX2007011165A (es) * 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
PL2254549T5 (pl) * 2008-03-17 2019-12-31 Alcon Research, Ltd. Wodne kompozycje farmaceutyczne zawierające kompleksy boran-poliole
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
JP2010275259A (ja) * 2009-05-29 2010-12-09 Toa Yakuhin Kk 均一、かつ安定なラタノプロスト点眼液剤組成物
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸-多元醇錯合物之水性藥學組成物
EP2269575A1 (en) 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Method for improving bioavailability of latanoprost
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
WO2012015998A2 (en) 2010-07-29 2012-02-02 Allergan, Inc. Preservative free bimatoprost and timolol solutions
EP2598117A2 (en) * 2010-07-29 2013-06-05 Allergan, Inc. Preservative free bimatoprost solutions
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
AU2013245946A1 (en) * 2012-04-10 2014-11-27 Eyenovia, Inc. Spray ejector mechanisms and devices providing charge isolation and controllable droplet charge, and low dosage volume opthalmic administration
US20130299607A1 (en) 2012-04-20 2013-11-14 Corinthiam Ophthalmic, Inc. Spray ejector device and methods of use
KR102168906B1 (ko) 2012-05-14 2020-10-22 아이노비아 인코포레이티드 층류 액적 생성기 디바이스 및 이용 방법들
SG11201407431RA (en) 2012-05-15 2014-12-30 Eyenovia Inc Ejector devices, methods, drivers, and circuits therefor
CA2997744C (en) 2012-09-12 2019-12-31 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
CA3142049C (en) 2012-09-12 2023-08-29 Novaliq Gmbh Semifluorinated alkane compositions
WO2014081941A1 (en) 2012-11-21 2014-05-30 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
NO2753788T3 (enExample) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015029923A1 (ja) * 2013-08-26 2015-03-05 ロート製薬株式会社 眼科用製剤
GR1008483B (el) * 2013-12-23 2015-05-12 Rafarm Α.Ε.Β.Ε., Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
WO2016021371A1 (ja) 2014-08-05 2016-02-11 ソニー株式会社 直流電力送電装置、直流電力受電装置及び直流電力送電システム
DK3356313T3 (da) 2015-09-30 2020-07-20 Novaliq Gmbh 2-perfluorhexyloktan til oftalmisk indgivelse
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
JP2019520357A (ja) 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
WO2018054932A1 (en) 2016-09-22 2018-03-29 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
CN109906085B (zh) 2016-09-23 2024-03-08 诺瓦利克有限责任公司 含有环孢素的眼用组合物
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
SG11202002640YA (en) 2017-09-27 2020-04-29 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
CA3091308A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2019206956A1 (en) 2018-04-27 2019-10-31 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
MY206642A (en) 2018-10-12 2024-12-30 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
MD3886799T2 (ro) 2019-08-07 2024-01-31 Aneira Pharma Inc Compoziții pentru tratamentul căderii părului
AU2020340561A1 (en) 2019-09-06 2022-03-31 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
JP2022120120A (ja) * 2022-06-13 2022-08-17 東亜薬品株式会社 眼科用水性組成物及びプロスタグランジンF2α誘導体の含量の低下を抑制する方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420857T1 (de) * 1988-09-06 2009-01-15 Pfizer Health Ab Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
AU7680096A (en) 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
JPH10259179A (ja) * 1996-09-19 1998-09-29 Santen Pharmaceut Co Ltd 多置換アリールオキシ基を有するプロスタグランジン類およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
SE0002211D0 (sv) 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
AU2001286210A1 (en) 2000-09-13 2002-03-26 Asahi Glass Company, Limited Eye drops
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
US20030018079A1 (en) 2000-11-13 2003-01-23 Richardson Helene Treatment
US7249174B2 (en) * 2002-06-12 2007-07-24 Bladelogic, Inc. Method and system for executing and undoing distributed server change operations
US20050228048A1 (en) * 2002-08-23 2005-10-13 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
CA2498233C (en) 2002-09-09 2012-08-14 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient

Similar Documents

Publication Publication Date Title
JP2006503913A5 (enExample)
CA2502437A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
CN102811610B (zh) 无刺激性眼科聚维酮碘组合物
TWI298257B (en) Hypotensive lipid and timolol compositions and methods of using same
US8785393B2 (en) Ophthalmic pharmaceutical compositions of DP2 receptor antagonists
JP6014033B2 (ja) 防腐剤無添加ビマトプロストおよびチモロール溶液
US20080233053A1 (en) Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
JP2005523316A5 (enExample)
Kroll et al. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma
US20120027842A1 (en) Topical formulations of flap inhibitors for administration to an eye
JP2014515383A5 (enExample)
JP4933897B2 (ja) 眼内移行性促進水性点眼剤
ES2210018T3 (es) Antagonistas de 5ht-2 para regular la presion intraocular y tratar el glaucoma.
AU2011282679A1 (en) Preservative free bimatoprost solutions
JP5132015B2 (ja) 点眼剤組成物
JP5725786B2 (ja) 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物
Day et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension
JP2011518828A (ja) 眼球障害の処置のためのpai−1の発現および活性インヒビター
CN107412211A (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
KR20150119082A (ko) 국소 안구 진통제
ES2452026T3 (es) Prostaglandinas y análogos como agentes para disminuir la presión intraocular
JP5041761B2 (ja) 眼粘膜適用製剤
JP4470393B2 (ja) 安定である点眼剤
JPH08231400A (ja) イフェンプロジルを必須成分とする眼圧降下剤
Schacknow et al. Medications used to treat glaucoma